Pandemic strategising for cancer hospital stockpiles

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022

Update on the new EUSOMA quality indicators for breast cancer

Lung cancer in India

The global impact of the FDA's changing approval standards

Tumour agnostic treatments in GI cancer

ecancer-AORTIC special issue on cancer research training in Africa

Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs placebo for early-stage TNBC

Durvalumab plus chemotherapy significantly improved OS in advanced biliary tract cancer

Early treatment discontinuation and early oxaliplatin discontinuation for stage III colorectal cancer

HIMALAYA: Study of tremelimumab and durvalumab as first-line therapy in patients with uHCC

Comparing two chemo regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced oesophageal cancer